A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor α (PDGFRα) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS)

被引：0

作者：

Tap, William D.

Jones, Robin L.

Chmielowski, Bartosz

Elias, Anthony D.

Adkins, Douglas

Van Tine, Brian Andrew

Agulnik, Mark

Cooney, Matthew M.

Livingston, Michael B.

Pennock, Gregory K.

Qin, Amy

Shahir, Ashwin

Ilaria, Robert L.

Conti, Ilaria

Cosaert, Jan

Schwartz, Gary K.

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[2] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[3] UCLA Melanoma Sarcoma Program, Los Angeles, CA USA

[4] Univ Colorado Canc Ctr, Aurora, CO USA

[5] Washington Univ Sch Med St Louis, St Louis, MO USA

[6] Northwestern Univ, Chicago, IL 60611 USA

[7] Univ Hosp Case Med Ctr, Cleveland, OH USA

[8] Carolinas HealthCare Syst, Charlotte, NC USA

[9] Levine Canc Inst, Charlotte, NC USA

[10] Eli Lilly & Co, Bridgewater, NJ USA

[11] Eli Lilly & Co, Erl Wood, Surrey, England

[12] Eli Lilly & Co, Indianapolis, IN 46285 USA

[13] Columbia Univ Med Ctr, New York, NY USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

10501

引用

页数：1